

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients

Yufeng Song¹, Regan Myers¹, Frances Mehl¹, Lila Murphy^{1,2}, Bailey Brooks^{1,2}, Jeffrey
M. Wilson³, Alexandra Kadl^{4,5}, Judith Woodfolk⁴, Steven L. Zeichner^{1,6*}

¹Department of Pediatrics, University of Virginia

²College of Arts and Sciences, University of Virginia

³Division of Allergy and Clinical Immunology, Department of Medicine, University of
Virginia

⁴Department of Medicine, University of Virginia

⁵Department of Pharmacology, University of Virginia

⁶Department of Microbiology, Immunology, and Cancer Biology, University of Virginia

*Correspondence: zeichner@virginia.edu

22 **Abstract**

23 Many mechanisms responsible for COVID-19 pathogenesis are well-established, but
24 COVID-19 includes features with unclear pathogenesis, such as autonomic
25 dysregulation, coagulopathies, and high levels of inflammation. The receptor for SARS-
26 CoV-2 spike protein's receptor binding domain (RBD) is angiotensin converting enzyme
27 2 (ACE2). We hypothesized that some COVID-19 patients may develop antibodies that
28 have negative molecular image of RBD sufficiently similar to ACE2 to yield ACE2-like
29 catalytic activity - ACE2-like abzymes. To explore this hypothesis, we studied patients
30 hospitalized with COVID-19 who had plasma samples available obtained about 7 days
31 after admission. ACE2 is a metalloprotease that requires Zn^{2+} for activity. However, we
32 found that the plasma from some patients studied could specifically cleave a synthetic
33 ACE2 peptide substrate, even though the plasma samples were collected using
34 disodium ethylenediaminetetraacetate (EDTA) anticoagulant. When we spiked plasma
35 with synthetic ACE2, no ACE2 substrate cleavage activity was observed unless Zn^{2+}
36 was added or the plasma was diluted to decrease EDTA concentration. After processing
37 samples by 100 kDa size exclusion columns and protein A/G adsorption, which
38 depleted immunoglobulin by >99.99%, the plasma samples did not cleave the ACE2
39 substrate peptide. The data suggest that some patients with COVID-19 develop
40 antibodies with abzyme-like activity capable of cleaving synthetic ACE2 substrate. Since
41 abzymes can exhibit promiscuous substrate specificities compared to the enzyme
42 whose active site image they resemble, and since proteolytic cascades regulate many
43 physiologic processes, anti-RBD abzymes may contribute to some otherwise obscure
44 COVID-19 pathogenesis.

45

46

47 **Introduction**

48 The primary pathology in COVID-19 involves pulmonary disease¹⁻³. Other end organ
49 involvement, likely directly attributable to infection with the virus, can include
50 gastrointestinal disease, such as diarrhea, and loss of smell and taste²⁻⁴. While the
51 basic pathophysiology of COVID-19 is well-established, COVID-19 has many baffling
52 features, including disorders involving high inflammation, disorders of the clotting
53 cascade, and problems with blood pressure homeostasis^{2, 5, 6}. Some sequelae do not
54 develop until a week or more after infection, suggesting that their pathogenesis may
55 result from secondary processes.

56
57 Reports suggest that some of the inflammatory processes associated with COVID-19
58 may relate to antibodies against the SARS-CoV-2 spike protein, S. For example, small
59 numbers of children who have received COVID-19 vaccines and have had no evidence
60 of infection with SARS-CoV-2, as well as a small number of infants born to mothers with
61 COVID-19⁷ have been described as having multi-system inflammatory syndrome of
62 children (MIS-C)⁸.

63
64 In addition to acute COVID-19, some patients experience Post-Acute Sequelae of
65 SARS CoV-2 infection (PASC, sometimes called “long COVID”), a heterogeneous group
66 of symptoms that continue after acute infection has resolved and can include evidence
67 of a hyperinflammatory state⁹, persistent coagulopathies, and neurophysiologic
68 dysregulation, for example aberrant blood pressure regulation. While some clinical
69 features observable at the beginning of the COVID-19 clinical course, such as SARS-
70 CoV-2 viremia, autoantibodies, inflammatory markers, and activation of Epstein-Barr

71 Virus, may be associated with an increased risk of long COVID¹⁰, the detailed
72 pathogenic processes responsible for PASC remain unclear.
73
74 Membrane-bound angiotensin converting enzyme 2 (ACE2) is the main cellular receptor
75 for SARS-CoV-2. Binding of the SARS-CoV-2 spike protein receptor binding domain
76 (RBD) to ACE2 initiates the pathway that leads to infection of a new host cell. ACE2, a
77 Zn²⁺ metalloenzyme, cleaves angiotensin II into angiotensin 1-7, which has vasodilatory
78 activity. Angiotensin converting enzyme (ACE) cleaves angiotensin I to yield angiotensin
79 II, which has vasoconstrictive and hypertensive effects. ACE2 therefore helps to
80 counteract the hypertensive effects of angiotensin II, and so has blood pressure
81 counterregulatory activity compared to ACE. There have been isolated reports and
82 small case series describing persistent hypotension in patients with COVID-19 and
83 patients with PASC without a clearly identified cause¹¹⁻¹³.
84
85 The kallikrein-kinin system is a proteolytic cascade that helps regulate inflammation
86 (reviewed in ¹⁴). There is cross-talk between the coagulation, kallikrein-kinin,
87 complement and renin-angiotensin systems¹⁵. Some patients with severe COVID-19
88 respiratory disease have been found to have altered regulation of the kallikrein-kinin
89 system in bronchoalveolar lavage fluid¹⁶. Abnormalities in the kallikrein-kinin system
90 have been proposed as contributing to the pathogenesis of severe COVID-19¹⁷.
91
92 Catalytic antibodies, “abzymes”^{18, 19}, are antibodies that have catalytic activity. When
93 abzymes were first described, they generated considerable excitement. Investigators
94 hypothesized that it would be possible to produce clinically and biotechnologically useful
95 abzymes.

96

97 However, with additional studies, it became clearer that abzyme activity was
98 significantly lower than the activity of more conventional enzymes (k_{cat}/K_m values $\sim 10^2$
99 $- 10^4 \text{ s}^{-1} \cdot \text{M}^{-1}$ ²⁰ vs. k_{cat}/K_m values of $\sim 10^5 \text{ s}^{-1} \cdot \text{M}^{-1}$)²¹. Hence, interest in the
100 biotechnological applications of abzymes waned, but an appreciation of the potential
101 role of abzymes in the pathogenesis of disease, including autoimmune disease,
102 continued. High concentrations of abzymes in the circulation may compensate for the
103 abzymes' lower activity to yield clinically significant effects.

104

105 Patients with autoimmune diseases can make abzymes catalyzing, for example,
106 cleavage of vasoactive intestinal peptide (VIP)²², DNA²³, immunoglobulin components²⁴,
107 components of the clotting cascade²⁵⁻²⁷, and myelin basic protein (MBP) in patients with
108 multiple sclerosis²⁸. Abzymes that cleave the HIV envelope protein have been observed
109 to occur in patients with HIV, so there is precedence for the induction of a catalytic
110 antibody by a virus²⁹.

111

112 Investigators have deliberately made anti-idiotypic abzymes with catalytic activity like
113 the activity of a particular enzyme of interest^{30, 31}. Investigators identify an antibody
114 against an enzyme, and then produce an antibody against the anti-enzyme antibody.
115 For some of the anti-idiotypic antibodies, there is enough resemblance to the active site
116 of the enzyme that the anti-idiotypic antibody has catalytic activity resembling the
117 enzyme^{32, 33}. In some instances, the substrate specificity of the abzyme differs
118 substantially from that of the original enzyme^{31, 32, 34}, with the abzyme showing more
119 substrate promiscuity than the original enzyme.

120

121 The receptor binding domain of the SARS-CoV-2 spike protein uses the ACE2 enzyme
122 on the surface of the target future host cell as its receptor. The RBD is not an antibody,
123 but it does bind ACE2. Taking as an example of abzyme production the anti-idiotypic
124 antibody to an antibody against an enzyme, it is plausible to hypothesize that in some
125 cases, an antibody against the RBD might resemble the ACE2 active site and so have
126 catalytic activity. If an antibody directed against the RBD has some resemblance to
127 ACE2, it is also plausible that anti-RBD antibodies, for some small fraction of patients,
128 might have catalytic activity reminiscent of ACE2. We hypothesized that some COVID-
129 19 patients may develop anti-RBD antibodies, with promiscuous catalytic activity that, in
130 some cases, cleaves substrates in patients to yield clinically significant effects. FIG 1
131 outlines this hypothesis schematically. We therefore undertook a study to explore
132 whether some COVID-19 patients might have antibodies that can cleave an ACE2
133 substrate.

134
135 We studied plasma samples from a group of 67 patients, with samples obtained
136 relatively early in their disease course, on about the 7th day of hospitalization. As a
137 negative control we purchased pooled human plasma that was collected in late 2018,
138 about a year before the first cases of COVID-19 were described. We tested plasma
139 using an established fluorometric assay for ACE2 activity, which detects cleavage of an
140 ACE2 peptide substrate. We found that some of the patients had ACE2 substrate
141 peptide specific cleavage activity when the assay was run directly on disodium
142 ethylenediaminetetraacetate (EDTA)-anticoagulated plasma samples, even though
143 ACE2 is a metalloprotease that requires Zn^{2+} for activity. Recombinant ACE2 added to
144 plasma did not show ACE2 substrate-cleaving activity unless $ZnCl_2$ was added to
145 samples at concentrations greater than the EDTA. Processing the samples through a

146 100 KDa size exclusion column followed by absorption with protein A/G beads, which
147 depleted IgG by >99.99%, eliminated the ability of the samples to cleave the ACE2
148 peptide substrate, supporting the hypothesis that a fraction of COVID-19 patients may
149 develop antibodies that have ACE2 substrate cleavage activity.

150

151

152 **Methods**

153 **Clinical Cohort**

154 The clinical cohort was recently described in more detail in another publication³⁵. The
155 hypothesis motivating that work held that COVID-19 would lead to large scale
156 reactivation of lymphotropic herpesviruses EBV and HHV-6, but the data obtained in
157 the study did not support that hypothesis. In brief, the University of Virginia (UVA)
158 enrolled a prospective cohort of moderate to severe COVID-19 adult patients admitted
159 to the hospital with a diagnosis confirmed by a nucleic acid amplification test. Patients
160 consented were entered into the study. Clinical data were entered into study databases.
161 Plasma was collected into clinical standard lavender top (EDTA anticoagulant) tubes.
162 Samples were processed in the UVA Biorepository and Tissue Facility and stored at -80
163 C. Study participants (n=67) were adults ages 18 years and above. We used samples
164 obtained on or about day 7 of hospitalization for this study, prior to anti-inflammatory
165 drug administration (Table 1). The predominant viral strain for our sample was the alpha
166 strain with 98.51% of our sample (66 patients) being collected before July of 2021. The
167 sample collection protocol was approved by the UVA IRB (HSR #200110), and approval
168 was obtained to work on the specimens (HSR #HSR200362), and it follows the
169 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
170 guidelines. EDTA-anticoagulated healthy normal donor plasma was purchased from
171 Valley Biomedical (<http://www.valleybiomedical.com/>), (Pooled Human Plasma, Cat. No.
172 HP1051PK2, Lot No. 21M2548). This lot of plasma was collected on December 12,
173 2018 and December 13, 2018 (communication with Valley Biomedical technical
174 support), about a year before the start of the COVID-19 pandemic, so it is extremely
175 unlikely that the plasma was derived from any blood from patients infected with SARS-

176 CoV-2. Plasma was aliquoted and stored at -20°C according to manufacturer's
177 instructions.

178

179 **Angiotensin II Converting Enzyme (ACE2)-like Abzyme Activity Detection**

180 Abzyme catalytic activities in plasma samples were measured using an Angiotensin II
181 Converting Enzyme (ACE2) Activity Assay Kit, Fluorometric (Abcam, Cat. #ab273297)
182 according to the manufacturer's protocol. This assay employs a synthetic ACE2 peptide
183 substrate labeled with a fluor and a quencher. The manufacturer's product information
184 claims a lower limit of detection for an unmodified assay of 400 µU. The manufacturer
185 does not release detailed information concerning the peptide substrate, holding that
186 information as a trade secret. The kit includes recombinant human ACE2 (ACE2) for
187 use as a positive control. 50µl plasma was added to wells in a 96-well black flat bottom
188 assay plate (Corning, Cat. #3603) and incubated at room temperature (RT), in the dark
189 for 15 min. Then, 50µl of substrate pre-diluted according to manufacturer's protocol was
190 added into the wells of the plate, mixing the substrate with the plasma sample. 25µM
191 OMNIMMP® fluorogenic control substrate (Enzo Life Sciences, Cat. #MML-P127), Mca-
192 Pro-Leu-OH which is suggested as fluorogenic Mca control peptide by manufacturer
193 (<https://www.enzolifesciences.com/BML-P163/mca-apk-dnp/>), were added to the
194 samples as ACE2 activity specific negative controls as mentioned previously³⁶. The
195 plate was placed into a SpectraMax® M5 multi-model microplate reader (Molecular
196 Devices) and the Relative Fluorescent Unit (RFU, Ex/Em = 320/420 nm) values were
197 measured in kinetic mode every 20 min for a total of 16 hours at 37°C. ACE2 inhibitor
198 provided in the assay kit was also used for additional controls.

199

200 **ACE2 Substrate Peptide Cleavage Activity in Plasma Samples in the Presence**
201 **and Absence SARS-CoV-2 Spike Protein Synthetic Peptides**

202 To evaluate the specificity of ACE2 substrate cleavage activity by the plasma, we
203 designed tiled SARS-CoV-2 spike protein RBD peptides which covered RBD amino acid
204 sequence from residues Arg319 to Phe541 including receptor binding motif (RBM) from
205 Ser438 to Gln506 based on previous comprehensive structure analysis on viral-host
206 interaction³⁷, had them synthesized by SB-PEPTIDE (SmartBioscience SAS, France)
207 (Table 2). Plasma samples and positive control, purified recombinant human ACE2
208 protein provided in the ACE2 assay kit (Abcam, Cat. #ab273297), were incubated with
209 or without 5-fold serially diluted peptide pools at room temperature for 15min before
210 adding the substrate. Samples incubated with ddH₂O and DMSO which were equivalent
211 to the concentrations used in the peptide pool reconstitution served as negative
212 controls. Then 50 μ L of ACE2 substrate (pre-diluted according to manufacturer's
213 protocol) was added into the wells and the samples were assayed. Relative Fluorescent
214 Units were measured, and data was analyzed as described below.

215

216 **Determination of ACE2 Substrate Peptide Cleavage Activity in Plasma Samples**
217 **With and Without Added ZnCl₂ or Plasma Dilution**

218 To evaluate whether native ACE2 shed into blood^{38, 39} could contribute to the catalytic
219 activity observed in the patient plasma samples, we investigated whether EDTA present
220 in the plasma samples inhibited activity of recombinant ACE2 spiked into the samples.
221 EDTA can inhibit the catalytic activity of ACE2, a Zn²⁺ metalloprotease^{40, 41}.

222

223 We conducted serial 10-fold dilutions of the normal donor plasma in ACE2 assay buffer
224 from the assay kit and then added 2 μ L recombinant positive control ACE2, provided as

225 a positive control in the ACE2 assay kit (Abcam, Cat. #ab273297) to each well to the
226 samples to the samples according to the manufacturer's protocol, conducting the ACE2
227 assays on the serially diluted samples with the added recombinant ACE2. We also
228 added ZnCl₂ to some samples to achieve final concentrations ranging from 0 to 2 mM.
229 Samples containing plasma, recombinant ACE2 and ZnCl₂ mixture with pre-diluted
230 ACE2 inhibitor served as negative comparisons. Then, 50 μL of substrate (pre-diluted
231 according to manufacturer's protocol) was added into the wells. Relative Fluorescent
232 Units were measured, and data was analyzed as described below.

233

234 **Human Immunoglobulin Depletion and Detection**

235 To deplete immunoglobulins from the samples, patient plasma samples or pooled
236 healthy donor plasma were centrifuged at 12,000 g at 4 °C for 15 min and supernatants
237 were passed through a 0.45 μm syringe filter (FisherScientific, Cat. #97204) to remove
238 contaminating particulate matter. We then placed 500 μL of the filtered samples into
239 ultrafiltration columns with 100kDa cut-off ultrafiltration membrane (Pierce™ Cat. #
240 88503) and centrifuged the columns at 12,000 × g at 4 °C until > 400 μL of filtrate was
241 produced. To further deplete antibodies in the plasma samples, we then incubated the
242 flow-through fractions with 30 μL pre-washed Protein A/G Magnetic Beads (Life
243 Technologies, Cat. # 88803, 10 mg/mL) at room temperature (RT) for 1 hour, followed
244 by magnetic removal of the beads, and repeated the same incubation procedure with
245 another freshly prepared 30 μL magnetic beads. The resulting processed plasma
246 samples were stored at 4°C for short times (less than 12 hours) or -20 °C for longer
247 times. Human IgG was measured using a Human IgG ELISA Kit (Abcam, Cat.
248 #ab100547) according to the manufacturer's protocol. We added 50 μL processed
249 samples, as well as standards to multi-microwell strips and incubated them at room

250 temperature for 2.5 hours. Strips were washed with wash buffer and 50 μ L diluted
251 biotin-labeled IgG detection antibody were then added to each well with subsequent
252 HRP-streptavidin incubation after another wash step. Each incubation was performed at
253 room temperature for at least 1 hour. After washing, 100 μ L of TMB One-Step Substrate
254 was added to each well and was incubated for 5 to 15 min at room temperature in the
255 dark with gentle shanking. The reaction was stopped by adding 50 μ L Stop Solution to
256 each well. OD values were read at 450 nm using an accuSkan FC micro-well plate
257 reader (ThermoFisher). IgG concentrations were calculated based on standard curves
258 generated with the same batch of assay strips. Human IgM was measured using a
259 Human IgM ELISA Kit (Invitrogen, Cat. #BMS2098) according to the manufacturer's
260 protocol. Briefly, after washing the strips twice, we added 100 μ L processed samples,
261 as well as standards together with 50 μ L HRP-conjugated antibody to multi-microwell
262 strips and incubated them at room temperature for at least 1 hour. Strips were washed
263 with wash buffer. After washing, 100 μ L of TMB One-Step Substrate was added to each
264 well and was incubated for 5 to 15 min at room temperature in the dark with gentle
265 shanking. The reaction was stopped by adding 100 μ L Stop Solution to each well. OD
266 values were read at 450 nm using an accuSkan FC micro-well plate reader
267 (ThermoFisher). IgM concentrations were calculated based on standard curves
268 generated with the same batch of assay strips.

269

270 **RBD Binding Assays**

271 We measured IgG binding to the S-RBD in serum with a quantitative ImmunoCAPTM-
272 based system, employing a Phadia 250 (Thermo-Fisher/Phadia), as described⁴². In
273 brief, we biotinylated S-RBD (RayBiotech, Peachtree Corners, GA) and conjugated it to
274 streptavidin-coated ImmunoCAPTMs (Thermo-Fisher/Phadia). We subtracted

275 background signal by subtracting the signal due to unconjugated streptavidin

276 ImmunoCAP™, which was run in parallel with each sample.

277

278 **Data Analysis**

279 Since the RFU values for the assays conducted on the samples reached 80% of

280 maximum at about 240 min, RFU values observed over 240 min generated by an ACE2

281 kit were used to evaluate ACE2 substrate cleavage activity in the plasma samples. For

282 each sample, a value corrected for baseline fluorescence in the sample was obtained

283 by the subtracting the baseline RFU value from the value at each subsequent time and

284 the sum of the baseline-corrected RFU values over 240 min was calculated using Excel.

285 Normalized RFU in FIG 6 were calculated as following formulation:

$$(\mathbf{RFU}_{actual} - \mathbf{RFU}_{minimum}) / (\mathbf{RFU}_{maximal} - \mathbf{RFU}_{minimum})$$

286 For SARS-CoV-2 spike RBD peptide competition assay, the AUCs (area under curve) of

287 each selected sample with individual incubation peptide pool amount were calculated

288 based on all RFU readouts. Subsequent statistical analysis and data visualization was

289 done using R (version 4.2.1) with the Rstudio environment and packages ggplot2,

290 tidyverse, readr, drc, ggpubr, ggh4x, gridExtra, and scales. Samples with the top 20%

291 and a control bottom 10% RFU values over 240 min were identified for antibody

292 depletion and further assays.

293

294

295 Results

296 To develop assays with enhanced sensitivity for ACE2 substrate cleavage activity, we
297 used a commercially available kit, in which a synthetic peptide ACE2 substrate labeled
298 with a fluor and a quencher is exposed to sample. ACE2 substrate cleavage activity
299 frees the fluor from quenching, followed by fluorometric evaluation over time. We first
300 established the kit's performance characteristics on commercially purchased EDTA-
301 anticoagulated normal human plasma. ACE2 is as Zn^{2+} -requiring metalloenzyme. Since
302 EDTA was used as the anticoagulant, to make Zn^{2+} unavailable to the Zn^{2+} -requiring
303 metalloenzymes of the enzymes involved in the coagulation cascade, we first
304 established whether exogenously added ACE2 could be detected when added to
305 plasma samples under our assay conditions. We found that exogenously added
306 recombinant ACE2 could not be detected, either using commercially obtained pooled
307 plasma or in plasma samples pooled from our patients and obtained from our sample
308 bank, unless Zn^{2+} was added or unless the plasma was diluted (FIG 2). Since no native
309 ACE2 activity should be detectable in the EDTA-anticoagulated plasma, any ACE2
310 substrate cleavage activity observed in the EDTA-anticoagulated plasma should be due
311 to something other than ACE or another Zn^{2+} metalloprotease.

312
313 We performed the ACE2 assay on EDTA-anticoagulated (obtained using clinical
314 standard lavender top tubes) research participant plasma samples obtained at about the
315 7th day of hospitalization for a cohort of 67 COVID-19 patients with moderate to severe
316 disease. Using these samples, without dilution and without added Zn^{2+} , we found that
317 we could detect cleavage of the ACE2 peptide substrate in some of the patients,
318 suggesting that the ACE2 peptide substrate cleavage activity was produced by an agent

319 with co-factor characteristics different from canonical ACE2 (FIG 3). FIG 4 shows a
320 scatter plot of the RFU values for the 67 patients studied.
321
322 To determine whether the ACE2 substrate cleavage activity was associated with the
323 presence of immunoglobulin in the samples, we developed an immunoglobulin depletion
324 protocol that includes an initial 0.45 um filtration step to remove large aggregates,
325 followed by a 100 KDa size exclusion column chromatography step, and a subsequent
326 staphylococcal A/G bead absorption step. To test whether patients with high RFU had
327 ACE2 substrate cleavage activity associated with immunoglobulin, we selected samples
328 from patients who had RFU values in the top 20% RFU values and which still had
329 sufficient plasma samples remaining for the immunoglobulin depletion procedure and
330 subsequent ACE2 assays. This selection yielded samples from 11 patients, 4, 5, 9, 11,
331 13, 15, 27, 43, 44, 47, and 48. We also selected samples from 3 patients (17, 64, 64)
332 who were among the patients having the bottom 10% of ACE2 substrate cleavage
333 activity and for which sufficient sample was available for the immunoglobulin depletion
334 procedure as negative control. To determine whether our immunoglobulin depletion
335 procedure also depleted IgM in addition to IgG, selected additional samples for which
336 there sufficient plasma remained for the assays, patients 4, 5, 11, 13, 15, 27, 43, 44, 64,
337 and the pooled healthy donor plasma, and determined IgM concentrations before and
338 after immunoglobulin depletion. We also included a purchased pooled EDTA-
339 anticoagulated plasma sample as an additional control. For both IgG and IgM, we found
340 that our depletion procedure removed more than 99.99% of the immunoglobulins.
341
342 Table 3 show the results of the immunoglobulin depletion protocol applied to the patient
343 plasma samples from these patients. The process depleted IgG by a factor of

344 >>99.99%, leaving IgG in the samples at <2.5 ng/ml for all samples. Table 4 shows the
345 results of assays for IgM run on selected samples for which sufficient sample remained
346 for the assays. For all samples assayed, the immunoglobulin depletion procedure
347 removed >99.9% of IgM.

348
349 We then re-assayed these samples to determine whether immunoglobulin depletion
350 was associated with elimination of the ACE2 substrate cleavage activity (FIG 5), and
351 found that for the 11 tested patients with ACE2 substrate cleavage activity in this cohort,
352 depletion of the immunoglobulin was accompanied by elimination of ACE2 substrate
353 cleavage activity.

354
355 To determine whether the cleavage activity was specific, we used a control substrate,
356 OMNIMMP® fluorogenic control (Enzo Life Sciences, Cat. #MML-P127), compared with
357 ACE2 standard substrate, Mca-APK(Dnp), provided by the assay kit according to a
358 previous study³⁶. Our pre-optimization study indicated 25μM of control substrate had
359 similar background level with standard substrate when incubated with purified
360 recombinant hACE2 positive control provided by the assay kit. Plasma samples with
361 ACE2-like activity were incubated with Mca-APK(Dnp) as well as 25μM OMNIMMP®
362 fluorogenic control substrate and fluorescence were read every 20min for 16 hours. The
363 plasma samples with ACE2-like activity when incubated with Mca-APK(Dnp), had no
364 activity when assayed with the OMNIMMP control substrate (FIG 6). A consensus
365 sequence of Pro-X-Pro-hydrophobic/basic for the protease specificity of ACE2 has been
366 defined^{43, 44}. Unlike Mca-YVADAPK(Dnp), a previously used substrate for caspase-
367 1/interleukin-converting enzyme (ICE) and ACE-2^{44, 45}, Mca-APK(Dnp) is not cleaved
368 by caspases and Mca fluorescence is quenched by the Dnp group until cleavage (at

369 Pro-Lys) separates them. OMNIMMP® fluorogenic substrate, Mca-Pro-Leu-OH, is used
370 as fluorogenic Mca control peptide for Mca-APK(Dnp) substrate by the manufacturer.
371 Studies also demonstrated that peptide substrates with similar sequences could not be
372 hydrolyzed by human ACE2^{43, 46}. This indicates that the catalytic activities of those
373 samples were specific ACE2-like activities. We also incubated samples with a synthetic
374 SARS-CoV-2 spike RBD peptide pool before adding the substrate to determine if the
375 RBD peptide pool would compete with the ACE2 substrate. We conducted 5-fold serial
376 dilutions of the peptide pools, starting at 10 μ g per peptide, incubating the peptide
377 competitors with plasma samples and ACE2 standard substrate, Mca-APK(Dnp). The
378 ability to cleave the ACE2 substrate were inhibited by RBD peptides in a dose
379 dependent manner (FIG 7 and Supplementary FIG 1) which suggested that the tiled
380 peptides covering the RBD region of SARS-CoV-2 spike competitively inhibits the
381 ACE2-like activities in plasma, further confirming the specificity of the ACE2-like
382 activities in plasma.

383
384 If our hypothesis is correct and the ability to cleave an ACE2 substrate is related to Abs
385 against the RBD, then we should be able to observe a correlation between ACE2
386 substrate cleavage activity and the amount of Ab directed against the RBD in the
387 patients' samples. We assayed for anti-RBD Ab binding activity using a modification of
388 an ImmunoCAP™ Assay activity using a Phadia 250 instrument and S-RBD (FIG 8). We
389 found that there was a significant correlation between the amount of Ab in the patient
390 plasma samples capable of binding the RBD and the ACE2 substrate cleavage activity,
391 suggesting that the ACE2 cleavage activity was related to the amount of anti-RBD Ab
392 present in the plasma sample.

393

394

395

396

397 **Discussion**

398 Our experiments indicate that a fraction of patients with COVID-19 have an activity in
399 plasma capable of cleaving a substrate for ACE2. The ACE2 substrate cleavage activity
400 has divalent cation requirements different from native ACE2 and collocates with
401 immunoglobulin presence during an immunoglobulin depletion procedure, suggesting
402 that these patients may have antibodies with abzyme activity.

403
404 The ACE2 substrate cleavage activity showed a significant correlation with Ab directed
405 against the RBD, further supporting the hypothesis that some anti-RBD Abs have ACE2
406 substrate cleavage activity, but there was considerable spread in the identification of
407 ACE2 substrate cleavage activity observed for different levels of anti-RBD Ab. However,
408 this spread would be expected if only a small fraction of Abs elicited against the RBD in
409 fact had ACE2 substrate cleavage activity, with the initiation and maturation of Ab
410 responses directed against the RBD resulting, in part, from non-specific processes.

411
412 Since abzymes can have a broadened substrate specificity compared to the original
413 enzyme that they mirror, it is possible that abzymes made in response to SARS-COV-2
414 infection may cleave a range of substrates, including substrates that form components
415 of important regulatory cascades, like clotting, blood pressure regulation, and
416 inflammation processes, which could account for aspects of COVID-19 that cannot be
417 directly attributed to viral infection and cell and tissue destruction.

418
419 Our study had several strengths. We studied a moderate number of patients, with
420 samples collected prospectively from acutely hospitalized patients with clearly
421 established COVID-19 relatively early in their disease course, but likely approaching at

422 least 2 weeks following initial infection. The patients almost certainly were not admitted
423 immediately following initial infection and the samples were obtained about a week after
424 admission, providing enough time for the development of an initial antibody response to
425 SARS-CoV-2 infection. We used a standard, widely-employed kit for ACE2 peptide
426 substrate cleavage activity^{36, 44, 47} of which the ACE2 standard substrate, Mca-
427 APK(Dnp), was previously developed as an improved fluorescence substrate with more
428 efficient intramolecular fluorescence quenching and enhanced fluorescence increase
429 over background after complete hydrolysis compared with other peptide substrates⁴⁴,
430 standard size exclusion columns, protein A/G bead absorption immunoglobulin
431 depletion techniques, and assays for immunoglobulins. The data showing that the ACE2
432 substrate cleavage activity was present even when there was sufficient EDTA to chelate
433 the Zn²⁺ essential for ACE2 activity suggests that the ACE2 substrate cleavage activity
434 had important characteristics different from native ACE2. The catalytic activities in
435 plasma were ACE2 substrate specific and were competitively inhibited by peptides
436 covering the SARS-CoV-2 spike RBD, further indicating that the cleavage activity was
437 specific. The data that the ACE2 substrate cleavage activity was removed from the
438 samples following processing with size exclusion columns and absorption with protein
439 A/G beads suggests that the non- Zn²⁺-requiring ACE2 substrate cleavage activity co-
440 localizes with immunoglobulin and the data that ACE2 substrate cleavage activity
441 correlated with Ab against the RBD support the hypothesis that the patients with ACE2
442 substrate cleavage activity may have developed abzymes with this activity.

443

444 However, our study has several limitations. We only studied a limited subset of the
445 patients admitted to our hospital, from patients who consented to the sample banking
446 and study and for whom sufficient sample volumes were available. A

447 contemporaneously collected, matched, prospective set of samples from patients
448 without COVID-19 would have been ideal negative controls, but samples from such
449 subjects were not obtained as part of the sample banking effort. We also only
450 conducted the assays on patient samples obtained at a single time, about 7 days after
451 hospitalization, so we have no data from patients who were discharged, transferred, or
452 died prior to day 7 of hospitalization. For this study, we were unable to correlate the
453 presence of ACE-2 abzyme activity with clinical disease features. More importantly, in
454 this study we have no data from patients later in their disease course or following
455 convalescence from the acute disease. Inflammatory, coagulopathic, and physiologic
456 dysregulatory phenomena predominate in the later stages of COVID-19 and at least
457 some aspects of PASC and MIS-C appear to result from immune-mediated phenomena.
458 However, some of these patients are treated with anti-inflammatory agents, including
459 intravenous immunoglobulin, which would make the study of these patients for abzyme-
460 like activity difficult. If abzymes with promiscuous substrate specificities develop in some
461 COVID-19 patients, some of the clinical features of those disorders could potentially be
462 attributed to abzymes, but this study is not able to directly address such additional
463 hypotheses, which would require additional work. In addition, since abzymes can show
464 substantial substrate specificity spread, it is possible that additional patients in our
465 cohort had abzymes with substrate specificity sufficiently divergent from
466 angiotensinogen that it was not detectable using our assay. It is also possible that
467 COVID-19 patients develop anti-RBD antibodies with abzyme-like activity, but that these
468 antibodies have no clinical significance. Some fraction of normal individuals may have
469 ACE2-like abzyme activity, but this activity could have been diluted in the purchased
470 pooled normal control plasma. However, if the abzyme activity in such patients was
471 similar to that observed in the individual positive patients in this study, that activity would

472 still be ~15% of the activity of the positive patients, given the prevalence of detectable
473 abzyme activity in our cohort, and so would have been likely detectable.

474

475 Finally, our study is merely associational. It is possible that we depleted some other,
476 non-immunoglobulin component of COVID-19 patient plasma that has the ability to
477 cleave the ACE2 substrate peptide with our 100 kDa size exclusion plus protein A/G
478 treatment procedure. To unequivocally establish that some COVID-19 patients develop
479 anti-SARS-CoV-2 immune responses that include abzymes, it would be necessary to
480 isolate discrete monoclonal antibodies from patients with ACE2 substrate cleavage
481 activity, and then characterize those monoclonal antibodies in detail. Such work lies
482 outside the perimeters of this current study. Additional studies of potential abzyme-like
483 activity in COVID-19 patients with different clinical disease manifestations and at
484 different points in their disease course, including long after acute COVID-19, would be
485 needed to establish the overall significance of abzymes in COVID-19 disease. While
486 understanding the detailed pathogenic significance of abzymes in COVID-19 still
487 requires substantial investigation, the existence of abzymes in COVID-19 is increasingly
488 well-established. In addition to the studies reported here, McConnell and co-workers⁴⁸
489 recently described the existence of abzymes in convalescent plasma COVID-19
490 patients capable of cleaving spike protein with virus neutralization. That two different
491 groups independently found evidence of abzyme activity in plasma from COVID-19
492 patients provides significant support for the hypothesis that COVID-19 patients can
493 develop antibodies with proteolytic activity.

494

495 Nevertheless, our study offers potential additional insight into some of the difficult-to-
496 understand clinical features of COVID-19, and if some of the difficult manifestations of

497 COVID-19 are related to the induction of antibodies with abzyme-like activity, that
498 finding may suggest new therapeutic interventions. Some other viruses also have also
499 evolved to use enzymes located on the target host cell surface as their receptors, so it
500 is conceivable that those other viral infections may also elicit clinically problematic anti-
501 viral antibodies. The number of spike protein RBDs presented to the immune system in
502 a natural infection is vastly greater than the number of RBDs presented to the immune
503 system following vaccination, offering many more opportunities for the induction of wide-
504 ranging antibody responses, unlike the antigen exposure resulting from vaccination.
505 While complications following vaccination are very rare and the risk-benefit calculation
506 greatly favors vaccination, some of the adverse side effects of SARS-CoV-2 vaccines
507 might also be attributable to the rare induction of anti-RBD antibodies with catalytic
508 activity.

509

510 **Institutional Review Board Statement:** The sample collection protocol was approved
511 by the UVA IRB (HSR #200110), and approval was obtained to work on the specimens
512 (HSR #HSR200362).

513

514 **Informed Consent Statement:** Informed consent was obtained from all participants
515 involved in the study.

516 **Data Availability Statement:** Data is presented in the manuscript and the
517 supplements. Raw data can be obtained on request.

518

519 **Acknowledgments and Funding:** The study was supported by internal funding from
520 the University of Virginia, including the Manning Fund for COVID-19 Research at UVA
521 the Ivy Foundation, the Pendleton Laboratory Fund for Pediatric Infectious Disease

522 Research, a College Council Minera Research Grant, the Coulter Foundation, and
523 NIAID, NIH (R01 AI176515) with sample acquisition costs supported by the HHV-6
524 Foundation. We thank the study participants for graciously agreeing to be research
525 participants, and the research support staff who enrolled the study participants (led by
526 Linda Bailes RN, Allison Raymond RN and Sarah Struchen RN). We also thank the
527 University of Virginia Biorepository and Tissue Research Facility for processing the
528 samples used in the study and for providing specimens (Technical Director, Patcharin
529 Pramoonjago PhD). We also want to appreciate Dr. John Lazo, Dr. Elizabeth Sharlow,
530 Dr. Kevin Lynch, and Stefan Hargett from Department of Pharmacology, University of
531 Virginia for their great help on instruments for the assays.

532

533 **Conflicts of Interest:** The authors declare no conflict of interest.

534

535 **Tables and Figures**

536

537

538

Table 1. Patient Demographic and Clinical Characteristics (cohort previously described in ³⁵)	
(IQR: interquartile range)	
Characteristic	N = 67, median, (IQR)
<i>Age at Admission</i>	60 (48, 66)
<i>First Weight (kg)</i>	91 (76, 112)
Unknown	1
<i>Height (m)</i>	1.68 (1.60, 1.83)
Unknown	6
<i>Gender</i>	
Female	28 (42%)
Male	39 (58%)
<i>Race</i>	
African American	23 (34%)
Native American	1 (1.5%)
Caucasian	31 (46%)
Other	12 (18%)
<i>Smoking Status</i>	
Current	1 (2.1%)
Former	14 (29%)
Never	24 (50%)
Unknown	9 (19%)
NA	19
<i>Need for ICU</i>	
No	28 (42%)
Yes	39 (58%)
<i>Need for Intubation</i>	
No	41 (61%)
Yes	26 (39%)
<i>Blood Type</i>	
A-	2 (4.8%)
A+	14 (33%)
AB+	1 (2.4%)
B+	3 (7.1%)
O-	1 (2.4%)
O+	21 (50%)
Not determined	25
<i>Highest Temperature</i>	
<38	42 (49%)
101	12 (18%)
>38.5	12 (18%)
>40	1 (1.5%)
<i>Length of Stay (Days)</i>	10 (5, 22)
<i>Time to Death (Days)</i>	
6	1
10-20	2
20-30	3
>30	2 (
<i>Highest D-Dimer</i>	605 (280, 2,074)
<i>Highest CRP</i>	10 (4, 16)
<i>BMI</i>	33 (27, 38)
<i>Need for Vasopressors</i>	
Yes	44 (66%)
<i>Dexamethasone</i>	
Yes	41 (61%)
<i>Prednisone</i>	
Yes	3 (13%)
<i>Methylprednisolone</i>	
Yes	5 (22%)
<i>Tocilizumab</i>	
Yes	4 (6%)
<i>Remdesivir</i>	
Yes	27 (40%)
<i>Creatinine</i>	1.00 (0.80, 1.45)
<i>Hgb</i>	12.4 (10.8, 13.6)
<i>IFNa3</i>	45 (36, 72)
Not determined	45
<i>Highest Ferritin</i>	1277 (7, 7161)
Not determined	5
<i>Highest Troponin</i>	
<0.04	47 (73%)
0.04-0.4	12 (18%)
>0.6	3 (5%)
Not determined	5
<i>Highest Creatinine</i>	1.10 (0.90, 1.80)

614 **Table 2.** SARS-CoV-2 Spike RBD Peptides for ACE2-like Activity Competition Inhibition Assay
615

RBD Peptide	Amino Acid Sequence	Reconstitution (10mg/ml)
319-335	RVQPTESIVRFPNITNL	DMSO
336-347	CPFGEVFNATRF	DMSO
348-357	ASVYAWNRKR	ddH ₂ O
352-365	AWNKRKISNCVADY	ddH ₂ O
371-394	SASFSTFKCYGVSP TKLNDLCFTN	DMSO
438-458	SNNLDSKVGGNYNLYRLFRK	ddH ₂ O
450-473	NYLYRLFRKSNLKP FERDISTEIY	ddH ₂ O
480-496	CNGVEGFNCYFPLQSYG	DMSO
500-509	TNGVGYPYR	DMSO
513-520	LSFELLHA	DMSO
523-541	TVCGPKKSTNLVKNKCVNF	ddH ₂ O

616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643

644 Table 3. Plasma IgG concentration before and after antibody depletion for selected
645 patients exhibiting ACE2 substrate cleavage activity in FIG 2, then re-assayed for ACE2
646 substrate cleavage activity with results shown in FIG 4.
647

648

Patient (#)	IgG Concentration		IgG depletion efficiency (%)
	Pre ^a mg/ml	Post ^b ng/ml	
4	14.62	0.67	>99.99%
5	12.50	1.48	>99.99%
9	24.40	0.96	>99.99%
11	75.41	0.17	>99.99%
13	26.35	2.46	>99.99%
15	13.27	2.47	>99.99%
27	10.53	2.40	>99.99%
43	29.07	0.87	>99.99%
44	11.17	2.29	>99.99%
47	13.15	1.85	>99.99%
48	12.32	2.06	>99.99%

649
650
651

a: IgG concentration in plasma before antibody depletion

b: IgG concentration in plasma after antibody depletion by ultrafiltration and Protein A/G beads

652 Table 4. Plasma IgM concentration before and after antibody depletion for selected
653 patients.
654

Patient (#)	IgM Concentration (mg/ml)		IgM Depletion Efficiency (%)
	Pre ^a	Post ^b	
4	0.875	1.43E-05	>99.99%
5	0.753	1.44E-05	>99.99%
11	0.7916	7.99E-06	>99.99%
13	0.644	1.41E-05	>99.99%
15	2.250	1.08E-05	>99.99%
27	0.549	1.40E-05	>99.99%
43	1.560	1.34E-05	>99.99%
44	3.243	1.41E-05	>99.99%
64	0.915	8.22E-06	>99.99%
Pooled Healthy Donor	0.4852	1.3568E-05	>99.99%

655 a: IgM concentration in plasma before antibody depletion

656 b: IgM concentration in plasma after antibody depletion by ultrafiltration and Protein A/G beads

657

658

659 Figure Legends

660

661 FIG 1. Schematic diagram illustrating the hypothesis underlying the study. The SARS-
662 COV-2 Spike Protein Receptor Binding Domain (RBD) binds ACE2 on the surface of a
663 potential host cells. The RBD has a partial negative image of ACE2. Some antibodies
664 against the RBD may then have a conformation sufficiently like ACE2 to have
665 proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further
666 suggests that the catalytic activity of some antibodies will have a substrate specificity
667 like ACE2, but because the negative image of RBD present antibodies is imperfect,
668 some antibodies with proteolytic activity will have an altered substrate specificity,
669 potentially affecting multiple proteolytic regulatory cascades.

670

671 FIG 2. Inhibition of exogenously added recombinant ACE2 substrate cleavage activity in
672 undiluted EDTA-anticoagulated pooled plasma samples with and without added ZnCl₂.
673 ACE2 is a Zn²⁺ metalloprotease. In this ACE2 spiking experiment, no ACE2 activity was
674 detectable when exogenous ACE2 was added to the plasma, unless Zn²⁺ was also

675 added, or unless the plasma was diluted prior to the addition of the spiked-in ACE2.
676 Adding an ACE2 inhibitor blocked detection of the ACE2 activity in all conditions,
677 indicating that the activity was specific for ACE2. The findings indicate that no native
678 ACE2 activity should be detectable in the EDTA-anticoagulated plasma and so any
679 ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should
680 be due to something other than ACE or another Zn²⁺ metalloprotease.

681
682 FIG 3. Survey of ACE2 substrate cleavage activity in plasma from 67 patients with
683 COVID-19 sampled at about day 7 of hospitalization. The plots present the results of the
684 fluorometric assays for ACE2 substrate cleavage activity run on the 67 patients, plus
685 control samples. Several patients, including the 11 patients we selected for further study
686 (4, 5, 9, 11, 13, 15, 27, 43, 44, 47, 48) because they had among the top 20% of RFU
687 values and had sufficient plasma sample remaining for the immunoglobulin depletion
688 protocol, showed an ability to cleave ACE2 substrate. (HDP: commercially purchased
689 pooled healthy donor plasma; HDP+P.C: HDP with added recombinant human ACE2;
690 HDP+P.C+I: HDP+P.C.+ ACE2; inhibitor; P.P.P alone: pooled plasma from negative
691 samples).

692
693 FIG 4. Scatter plot of the background corrected RFU values for the plasma samples
694 from the 67 patients evaluated in this study. The top 20% of values are plotted in red,
695 the middle 70% are plotted in black, and the bottom 10% are plotted in blue. The top
696 20% and bottom 10% were selected for the ACE2 substrate cleavage activity assays
697 before and after immunoglobulin depletion shown in FIG 5.

698

699 FIG 5. ACE2 substrate cleavage activity in patients before and after immunoglobulin
700 depletion. The figure shows ACE2 substrate cleavage activity for 11 patients (4, 5, 9,
701 11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values and for which
702 we had sufficient plasma for immunoglobulin depletion, before (blue points) and after
703 (red points) immunoglobulin depletion by a 100 KDa size exclusion column followed by
704 protein A/G bead absorption. We also show ACE2 substrate cleavage activity assays
705 before and after immunoglobulin depletion for pooled patient plasma (PPP) negative
706 controls and samples from three arbitrarily selected patients, 17, 64, 65, that had among
707 the bottom 10% of RFU values and had sufficient plasma remaining for the
708 immunoglobulin depletion protocol. The data suggest that for the 11 patients
709 demonstrating ACE2 substrate cleavage activity in this cohort, the ACE2 substrate
710 cleavage activity was depleted in an immunoglobulin-associated manner.

711
712 FIG 6. Substrate cleavage specificity of patient plasma. ACE2 substrate cleavage activity
713 specificities for 11 patients (4, 5, 9, 11, 13, 15, 27, 43, 44, 47, 48) who had among the
714 top 20% of RFU values were measured with ACE2 standard substrate (Mca-APK(Dnp))
715 and control substrate (OMNIMMP® fluorogenic control). All 11 samples as well as
716 positive control (ACE2 P.C.), purified recombinant human ACE2 provided by the assay
717 kit, had specific cleavage activities on Mca-APK(Dnp), but no activities on control
718 substrate. HDP: commercially purchased pooled healthy donor plasma as ACE2-activity
719 negative control sample.

720
721 FIG 7. Plasma ACE2-like activity competitive inhibition by SARS-CoV-2 spike RBD
722 peptides. ACE2 substrate cleavage activity for 11 patients (4, 5, 9, 11, 13, 15, 27, 43,
723 44, 47, 48) who had among the top 20% of RFU values were measured by incubation

724 with serial diluted SARS-CoV-2 spike RBD peptide pools. ACE2-like catalytic activities
725 in plasma were competitively inhibited by RBD peptide pool in a dose dependent
726 manner. AUCs of each curve from samples with individual peptide amount were
727 calculated based on all 16-hour RFU readouts. rhACE2: purified recombinant human
728 ACE2 provided by the assay kit as positive control. PPP: commercially purchased
729 pooled healthy donor plasma as ACE2-activity negative control sample.

730
731 FIG 8. Correlation of ACE2 substrate cleavage activity (ACE2 Activity) with anti-RBD
732 antibody (Ab Against RBD) in patient plasma. Anti-RBD antibody concentrations in
733 plasma samples were determined using ImmunoCAPTM antibody binding assay. The
734 negative control pooled human plasma is indicated by the red symbol. The patient
735 plasma sample are indicated in green. The negative control plasma values were omitted
736 in the calculation of the r- and p-values.


737

738 **Supplementary Data Legends**

739 S1. Supplementary Figure 1. Plasma ACE2-like activity competitive inhibition by SARS-
740 CoV-2 spike RBD peptides. A. ACE2 substrate cleavage activity for 11 patients (4, 5, 9,
741 11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values were
742 measured by incubation with serial diluted SARS-CoV-2 spike RBD peptide pools.
743 ACE2-like catalytic activities in plasma were competitively inhibited by RBD peptide pool
744 in a dose dependent manner. B. ACE2 activity of purified recombinant human ACE2
745 provided by the assay kit as positive control incubated with serial diluted SARS-CoV-2
746 spike RBD peptide pools. PPP: commercially purchased pooled healthy donor plasma
747 as ACE2-activity negative control sample.


748

749 FIG 1. Schematic diagram illustrating the hypothesis underlying the study. The SARS-
750 COV-2 Spike Protein Receptor Binding Domain (RBD) binds ACE2 on the surface of a
751 potential host cells. The RBD has a partial negative image of ACE2. Some antibodies
752 against the RBD may then have a conformation sufficiently like ACE2 to have
753 proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further
754 suggests that the catalytic activity of some antibodies will have a substrate specificity
755 like ACE2, but because the negative image of RBD present antibodies is imperfect,
756 some antibodies with proteolytic activity will have an altered substrate specificity,
757 potentially affecting multiple proteolytic regulatory cascades.
758
759
760




761
762

763 FIG 2. Inhibition of exogenously added recombinant ACE2 substrate cleavage activity in
764 undiluted EDTA-anticoagulated pooled plasma samples with and without added $ZnCl_2$.
765 ACE2 is a Zn^{2+} metalloprotease. In this ACE2 spiking experiment, no ACE2 activity was
766 detectable when exogenous ACE2 was added to the plasma, unless Zn^{2+} was also
767 added, or unless the plasma was diluted prior to the addition of the spiked-in ACE2.
768 Adding an ACE2 inhibitor blocked detection of the ACE2 activity in all conditions,
769 indicating that the activity was specific for ACE2. The findings indicate that no native
770 ACE2 activity should be detectable in the EDTA-anticoagulated plasma and so any
771 ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should
772 be due to something other than ACE or another Zn^{2+} metalloprotease.
773




774
775

776 FIG 3. Survey of ACE2 substrate cleavage activity in plasma from 67 patients with
777 COVID-19 sampled at about day 7 of hospitalization. The plots present the results of the
778 fluorometric assays for ACE2 substrate cleavage activity run on the 67 patients, plus
779 control samples. We identified plasma from 11 patients (4, 5, 9, 11, 13, 15, 27, 43, 44,
780 47, 48) that showed an ability to cleave ACE2 substrate. (HDP: commercially
781 purchased pooled healthy donor plasma; HDP+P.C: HDP with added recombinant
782 human ACE2; HDP+P.C+I: HDP+P.C.+ ACE2; inhibitor; P.P.P alone: pooled plasma
783 from negative samples).




784
785

786 FIG 4. Scatter plot of the background corrected RFU values for the plasma samples
787 from the 67 patients evaluated in this study. The top 20% of values are plotted in red,
788 the middle 70% are plotted in black, and the bottom 10% are plotted in blue. The top
789 20% and bottom 10% were selected for the ACE2 substrate cleavage activity assays
790 before and after immunoglobulin depletion shown in FIG 5.
791
792
793




794
795

796 FIG 5. ACE2 substrate cleavage activity in patients before and after immunoglobulin
797 depletion. The figure shows ACE2 substrate cleavage activity for 11 patients (4, 5, 9,
798 11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values and for which
799 we had sufficient plasma for immunoglobulin depletion, before (blue points) and after
800 (red points) immunoglobulin depletion by a 100 kDa size exclusion column followed by
801 protein A/G bead absorption. We also show ACE2 substrate cleavage activity assays
802 before and after immunoglobulin depletion for pooled patient plasma (PPP) negative
803 controls and samples from three arbitrarily selected patients, 17, 64, 65, that had among
804 the bottom 10% of RFU values and had sufficient plasma remaining for the
805 immunoglobulin depletion protocol. The data suggest that for the 11 patients
806 demonstrating the highest ACE2 substrate cleavage activity in this cohort, the ACE2
807 substrate cleavage activity was depleted in an immunoglobulin-associated manner.
808




809
810

811 FIG 6. Substrate cleavage specificity of patient plasma. ACE2 substrate cleavage activity
812 specificities for 11 patients (4, 5, 9, 11, 13, 15, 27, 43, 44, 47, 48) who had among the
813 top 20% of RFU values were measured with ACE2 standard substrate (Mca-APK(Dnp))
814 and control substrate (OMNIMMP® fluorogenic control). All 11 samples as well as
815 positive control (ACE2 P.C.), purified recombinant human ACE2 provided by the assay
816 kit, had specific cleavage activities on Mca-APK(Dnp), but no activities on control
817 substrate. HDP: commercially purchased pooled healthy donor plasma as ACE2-activity
818 negative control sample.
819
820




821
822
823
824
825
826
827
828
829
830
831
832

833 FIG 7. Plasma ACE2-like activity competitive inhibition by SARS-CoV-2 spike RBD
834 peptides. ACE2 substrate cleavage activity for 11 patients (4, 5, 9, 11, 13, 15, 27, 43,
835 44, 47, 48) who had among the top 20% of RFU values were measured by incubation
836 with serial diluted SARS-CoV-2 spike RBD peptide pools. ACE2-like catalytic activities
837 in plasma were competitively inhibited by RBD peptide pool in a dose dependent
838 manner. AUCs of each curve from samples with individual peptide amount were
839 calculated based on all RFU readouts. rhACE2: purified recombinant human ACE2
840 provided by the assay kit as positive control. PPP: commercially purchased pooled
841 healthy donor plasma as ACE2-activity negative control sample.
842
843



844
845
846
847
848
849
850

851
852 FIG 8. Correlation of ACE2 substrate cleavage activity (ACE2 Activity) with anti-RBD
853 antibody (Ab Against RBD) in patient plasma. Anti-RBD antibody concentrations in
854 plasma samples were determined using ImmunoCAP™ antibody binding assay. The
855 negative control pooled human plasma is indicated by the red symbol. The patient
856 plasma sample are indicated in green. The negative control plasma values were omitted
857 in the calculation of the r- and p-values.
858
859
860



861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877

878 References

- 879 1. Bajema KL, Oster AM, McGovern OL, Lindstrom S, Stenger MR, Anderson TC,
880 Isenhour C, Clarke KR, Evans ME, Chu VT, Biggs HM, Kirking HL, Gerber SI, Hall AJ,
881 Fry AM, Oliver SE. Persons Evaluated for 2019 Novel Coronavirus - United States,
882 January 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Feb 14;69(6):166-70. PMC7017962
883
- 884 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X,
885 Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L,
886 Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients
887 infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020 Feb
888 15;395(10223):497-506. PMC7159299
889
- 890 3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the
891 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
892 72 314 Cases From the Chinese Center for Disease Control and Prevention. *Jama.*
893 2020 Apr 7;323(13):1239-42.
894
- 895 4. Chung TW, Sridhar S, Zhang AJ, Chan KH, Li HL, Wong FK, Ng MY, Tsang RK,
896 Lee AC, Fan Z, Ho RS, Luk SY, Kan WK, Lam SH, Wu AK, Leung SM, Chan WM, Ng
897 PY, To KK, Cheng VC, Lung KC, Hung IF, Yuen KY. Olfactory Dysfunction in
898 Coronavirus Disease 2019 Patients: Observational Cohort Study and Systematic
899 Review. *Open Forum Infect Dis.* 2020 Jun;7(6):ofaa199. PMC7284010
900
- 901 5. Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, Gao Y, Cai L, Wang Z, Yin P, Wang
902 Y, Tang L, Deng J, Mei H, Hu Y. Haematological characteristics and risk factors in the
903 classification and prognosis evaluation of COVID-19: a retrospective cohort study.
904 *Lancet Haematol.* 2020 Sep;7(9):e671-e8. PMC7351397
905
- 906 6. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B,
907 Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van
908 Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M,
909 Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo
910 C, Feldmann M, Parekh S, Merad M, Gnjjatic S. An inflammatory cytokine signature
911 predicts COVID-19 severity and survival. *Nat Med.* 2020 Oct;26(10):1636-43.
912 PMC7869028
913
- 914 7. De Rose DU, Pugnali F, Cali M, Ronci S, Caoci S, Maddaloni C, Martini L,
915 Santisi A, Dotta A, Auriti C. Multisystem Inflammatory Syndrome in Neonates Born to
916 Mothers with SARS-CoV-2 Infection (MIS-N) and in Neonates and Infants Younger
917 Than 6 Months with Acquired COVID-19 (MIS-C): A Systematic Review. *Viruses.*
918 2022;14(4):750.
919
- 920 8. Yousaf AR, Cortese MM, Taylor AW, Broder KR, Oster ME, Wong JM, Guh AY,
921 McCormick DW, Kamidani S, Schlaudecker EP, Edwards KM, Creech CB, Staat MA,
922 Belay ED, Marquez P, Su JR, Salzman MB, Thompson D, Campbell AP. Reported
923 cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA
924 who received a COVID-19 vaccine, December, 2020, through August, 2021: a
925 surveillance investigation. *Lancet Child Adolesc Health.* 2022 Feb 22. PMC8864018

- 926
927 9. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk
928 factors, and management. *Bmj*. 2021 Jul 26;374:n1648.
929
- 930 10. Su Y, Yuan D, Chen, D.G., Ng, R.H., Wang, K., Choi, J., Li, S., Hong, S., Zhang
931 R, Xie, J., Kornilov, S.A., Scherler, K., Pavlovitch-Bedzyk, A.J., Dong, S., Lausted, C.,
932 Lee, I., Fallen S, Dai, C.L., Baloni, P., Smith, B., Duvvuri, V.R., Anderson, K.G., Li, J.,
933 Yang, F., Duncombe, C.J. M, D.J., Rostomily, C., Troisch, P., Zhou, J., Mackay, S.,
934 DeGottardi, Q., May, D.H., Taniguchi R, Gittelman, R.M, Klinger, M., Snyder, T.M,
935 Roper, R., Wojciechowska, G., Murray, K., Edmark R, Evans, S., Jones, L., Zhou, Y.,
936 Rowen, L., Liu, R., Chour, W., Algren, H.A, Berrington,, W.R. W, J.A., Cochran, R.A.,
937 Micikas, M.E., the ISB-Swedish COVID19 Biobanking Unit, Terri Wrin, Petropoulos,
938 C.J., Cole, H.R., Fischer, T.D., Wei, W., Hoon, D.S.B., Price, N.D., Subramanian, N.,,
939 Hill JA, Hadlock, J., Magis, A.T., Ribas, A., Lanier, L.L., Boyd, S.D., Bluestone, J.A.,
940 Chu, H., Hood,, L. G, R., Greenberg, P.D., Davis, M.M., Goldman, J.D., Heath, J.R.,.
941 Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. *Cell*. 2022.
942
- 943 11. Hanidziar D, Bittner EA. Hypotension, Systemic Inflammatory Response
944 Syndrome, and COVID-19: A Clinical Conundrum. *Anesth Analg*. 2020
945 Sep;131(3):e175-e6. PMC7302068
946
- 947 12. Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, Lim
948 PB. Autonomic dysfunction in 'long COVID': rationale, physiology and management
949 strategies. *Clin Med (Lond)*. 2021 Jan;21(1):e63-e7. PMC7850225
950
- 951 13. Koudelka M, Sovová E. COVID-19 Causing Hypotension in Frail Geriatric
952 Hypertensive Patients? *Medicina (Kaunas)*. 2021 Jun 18;57(6). PMC8235779
953
- 954 14. Hillmeister P, Persson PB. The Kallikrein–Kinin system. *Acta Physiologica*.
955 2012;206(4):215-9.
956
- 957 15. Bekassy Z, Lopatko Fagerström I, Bader M, Karpman D. Crosstalk between the
958 renin-angiotensin, complement and kallikrein-kinin systems in inflammation. *Nat Rev*
959 *Immunol*. 2022 Jul;22(7):411-28. PMC8579187
960
- 961 16. Martens CP, Van Mol P, Wauters J, Wauters E, Gangnus T, Noppen B,
962 Callewaert H, Feyen JHM, Liesenborghs L, Heylen E, Jansen S, Pereira LCV, Kraisin S,
963 Guler I, Engelen MM, Ockerman A, Van Herck A, Vos R, Vandenbrielle C, Meersseman
964 P, Hermans G, Wilmer A, Martinod K, Burckhardt BB, Vanhove M, Jacquemin M,
965 Verhamme P, Neyts J, Vanassche T. Dysregulation of the kallikrein-kinin system in
966 bronchoalveolar lavage fluid of patients with severe COVID-19. *eBioMedicine*. 2022
967 2022/09/01/;83:104195.
968
- 969 17. Carvalho PRd, Sirois P, Fernandes PD. The role of kallikrein-kinin and renin-
970 angiotensin systems in COVID-19 infection. *Peptides*. 2021 2021/01/01/;135:170428.
971
- 972 18. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. *Science*. 1986 Dec
973 19;234(4783):1566-70.
974

- 975 19. Pollack SJ, Jacobs JW, Schultz PG. Selective chemical catalysis by an antibody.
976 Science. 1986 Dec 19;234(4783):1570-3.
977
- 978 20. Hilvert D. Critical analysis of antibody catalysis. Annu Rev Biochem.
979 2000;69:751-93.
980
- 981 21. Bar-Even A, Noor E, Savir Y, Liebermeister W, Davidi D, Tawfik DS, Milo R. The
982 moderately efficient enzyme: evolutionary and physicochemical trends shaping enzyme
983 parameters. Biochemistry. 2011 May 31;50(21):4402-10.
984
- 985 22. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic
986 hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 1989 Jun
987 9;244(4909):1158-62.
988
- 989 23. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov
990 AG. DNA hydrolyzing autoantibodies. Science. 1992 May 1;256(5057):665-7.
991
- 992 24. Paul S, Li L, Kalaga R, Wilkins-Stevens P, Stevens FJ, Solomon A. Natural
993 catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL
994 fragment. J Biol Chem. 1995 Jun 23;270(25):15257-61.
995
- 996 25. Thiagarajan P, Dannenbring R, Matsuura K, Tramontano A, Gololobov G, Paul S.
997 Monoclonal antibody light chain with prothrombinase activity. Biochemistry. 2000 May
998 30;39(21):6459-65.
999
- 1000 26. Wootla B, Dasgupta S, Dimitrov JD, Bayry J, Lévesque H, Borg JY, Borel-Derlon
1001 A, Rao DN, Friboulet A, Kaveri SV, Lacroix-Desmazes S. Factor VIII hydrolysis
1002 mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol. 2008 Jun
1003 1;180(11):7714-20.
1004
- 1005 27. Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N,
1006 Pashov A, Sultan Y, Hoebeke J, Kazatchkine MD, Kaveri SV. Catalytic activity of
1007 antibodies against factor VIII in patients with hemophilia A. Nat Med. 1999
1008 Sep;5(9):1044-7.
1009
- 1010 28. Ponomarenko NA, Durova OM, Vorobiev, II, Belogurov AA, Jr., Kurkova IN,
1011 Petrenko AG, Telegin GB, Suchkov SV, Kiselev SL, Lagarkova MA, Govorun VM,
1012 Serebryakova MV, Avalle B, Tornatore P, Karavanov A, Morse HC, 3rd, Thomas D,
1013 Friboulet A, Gabibov AG. Autoantibodies to myelin basic protein catalyze site-specific
1014 degradation of their antigen. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):281-6.
1015 PMC1324791
1016
- 1017 29. Ponomarenko NA, Vorobiev, II, Alexandrova ES, Reshetnyak AV, Telegin GB,
1018 Khaidukov SV, Avalle B, Karavanov A, Morse HC, 3rd, Thomas D, Friboulet A, Gabibov
1019 AG. Induction of a protein-targeted catalytic response in autoimmune prone mice:
1020 antibody-mediated cleavage of HIV-1 glycoprotein GP120. Biochemistry. 2006 Jan
1021 10;45(1):324-30.
1022

- 1023 30. Avalle B, Mistro D, Thomas D, Friboulet A. Polyclonal catalytic anti-idiotypic
1024 antibodies with a beta-lactamase activity. *Ann N Y Acad Sci.* 1996 Oct 12;799:172-5.
1025
- 1026 31. Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Abzyme generation using
1027 an anti-idiotypic antibody as the "internal image" of an enzyme active site. *Appl*
1028 *Biochem Biotechnol.* 1994 May-Jun;47(2-3):229-37; discussion 37-9.
1029
- 1030 32. Izadyar L, Friboulet A, Remy MH, Roseto A, Thomas D. Monoclonal anti-idiotypic
1031 antibodies as functional internal images of enzyme active sites: production of a catalytic
1032 antibody with a cholinesterase activity. *Proc Natl Acad Sci U S A.* 1993 Oct
1033 1;90(19):8876-80. PMC47463
1034
- 1035 33. Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Antiidiotypic antibodies as
1036 functional internal images of enzyme-active sites. *Ann N Y Acad Sci.* 1995 Mar
1037 31;750:265-70.
1038
- 1039 34. Ponomarenko NA, Pillet D, Paon M, Vorobiev, II, Smirnov IV, Adenier H, Avalle
1040 B, Kolesnikov AV, Kozyr AV, Thomas D, Gabibov AG, Friboulet A. Anti-idiotypic
1041 antibody mimics proteolytic function of parent antigen. *Biochemistry.* 2007 Dec
1042 18;46(50):14598-609.
1043
- 1044 35. Brooks B, Tancredi C, Song Y, Mogus AT, Huang M-LW, Zhu H, Phan TL, Zhu
1045 H, Kadl A, Woodfolk J. Epstein–Barr Virus and Human Herpesvirus-6 Reactivation in
1046 Acute COVID-19 Patients. *Viruses.* 2022;14(9):1872.
1047
- 1048 36. Ferrari M, Mekkaoui L, Ilca FT, Akbar Z, Bughda R, Lamb K, Ward K, Parekh F,
1049 Karattil R, Allen C, Wu P, Baldan V, Mattiuzzo G, Bentley EM, Takeuchi Y, Sillibourne J,
1050 Datta P, Kinna A, Pule M, Onuoha SC. Characterization of a Novel ACE2-Based
1051 Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2
1052 Variants. *Journal of Virology.* 2021;95(19):10.1128/jvi.00685-21.
1053
- 1054 37. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L,
1055 Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
1056 ACE2 receptor. *Nature.* 2020 2020/05/01;581(7807):215-20.
1057
- 1058 38. García-Escobar A, Vera-Vera S, Jurado-Román A, Jiménez-Valero S, Galeote G,
1059 Moreno R. Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic
1060 Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-
1061 19. *Biomolecules.* 2022 Jan 5;12(1). PMC8774087
1062
- 1063 39. Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, Liu J,
1064 Harville TO. Development of ACE2 autoantibodies after SARS-CoV-2 infection. *PLoS*
1065 *One.* 2021;16(9):e0257016. PMC8415618
1066
- 1067 40. Tanna A, Guarino L, Tam FWK, Rodriguez-Cubillo B, Levy JB, Cairns TD, Griffith
1068 M, Tarzi RM, Caplin B, Salama AD, Cook T, Pusey CD. Long-term outcome of anti-
1069 neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the
1070 international histological classification and other prognostic factors. *Nephrology Dialysis*
1071 *Transplantation.* 2014;30(7):1185-92.

- 1072
1073 41. Xiao F, Burns KD. Measurement of angiotensin converting enzyme 2 activity in
1074 biological fluid (ACE2). *Hypertension*: Springer; 2017. p. 101-15.
1075 42. Keshavarz B, Wiencek JR, Workman LJ, Straesser MD, Muehling LM, Canderan
1076 G, Drago F, Bonham CA, Sturek JM, Ramani C, McNamara CA, Woodfolk JA, Kadl A,
1077 Platts-Mills TAE, Wilson JM. Quantitative Measurement of IgG to Severe Acute
1078 Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP. *Int Arch Allergy*
1079 *Immunol.* 2021;182(5):417-24. PMC8018212
1080
1081 43. Guy JL, Jackson RM, Acharya KR, Sturrock ED, Hooper NM, Turner AJ.
1082 Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site,
1083 specificity requirements, and chloride dependence. *Biochemistry.* 2003 Nov
1084 18;42(45):13185-92.
1085
1086 44. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T,
1087 Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological
1088 peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J Biol*
1089 *Chem.* 2002 Apr 26;277(17):14838-43.
1090
1091 45. Enari M, Talanian RV, Wong WW, Nagata S. Sequential activation of ICE-like
1092 and CPP32-like proteases during Fas-mediated apoptosis. *Nature.* 1996 Apr
1093 25;380(6576):723-6.
1094
1095 46. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N,
1096 Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel
1097 angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I
1098 to angiotensin 1-9. *Circ Res.* 2000 Sep 1;87(5):E1-9.
1099
1100 47. Glasgow A, Glasgow J, Limonta D, Solomon P, Lui I, Zhang Y, Nix MA, Rettko
1101 NJ, Zha S, Yamin R, Kao K, Rosenberg OS, Ravetch JV, Wiita AP, Leung KK, Lim SA,
1102 Zhou XX, Hobman TC, Kortemme T, Wells JA. Engineered ACE2 receptor traps
1103 potentially neutralize SARS-CoV-2. *Proceedings of the National Academy of Sciences.*
1104 2020;117(45):28046-55.
1105
1106 48. McConnell SA, Sachithanandham J, Mudrak NJ, Zhu X, Farhang PA, Cordero
1107 RJB, Wear MP, Shapiro JR, Park HS, Klein SL, Tobian AAR, Bloch EM, Sullivan DJ,
1108 Pekosz A, Casadevall A. Spike-protein proteolytic antibodies in COVID-19 convalescent
1109 plasma contribute to SARS-CoV-2 neutralization. *Cell Chem Biol.* 2023 Jul
1110 20;30(7):726-38.e4. PMC10288624
1111
1112